

Theoharis C. Theoharides
Duraisamy Kempuraj
Michael Tagen
Pio Conti
Dimitris Kalogeromitros

Authors' addresses

Theoharis C. Theoharides^{1,2,3,4}, Duraisamy Kempuraj¹, Michael Tagen¹, Pio Conti⁵, Dimitris Kalogeromitros⁴

¹Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts – New England Medical Center, Boston, MA, USA.

²Department of Biochemistry, Tufts University School of Medicine and Tufts – New England Medical Center, Boston, MA, USA.

³Department of Internal Medicine, Tufts University School of Medicine and Tufts – New England Medical Center, Boston, MA, USA.

⁴Allergy Section, Attikon Hospital, Athens, Medical School, Athens, Greece.

⁵Immunology Division, Department of Cancer and Neuroscience, Chieti University Medical School, Chieti, Italy.

Correspondence to:

Theoharis C. Theoharides, PhD, MD
Department of Pharmacology and Experimental Therapeutics Tufts University School of Medicine
136 Harrison Avenue
Boston, MA 02111, USA
Tel.: (617) 636 6866
Fax: (617) 636 2456
E-mail: theoharis.theoharides@tufts.edu

Acknowledgements

Aspects of the work discussed were supported in part by grants awarded to T. C. T. from the Multiple Sclerosis Society (RG-1961-A-1), NIH (NS38326, AR47652, DK62861, DK42409, DK 44816, DK and NS55681), DOD (BC024430), and Theta Biomedical Consulting and Development Co., Inc. (Brookline, MA, USA). We thank Ms Jessica Christian for her patience and word processing skills. T. C. T. discloses that he has been awarded US patent No. 5,250,529; No. 6,020,305; No. 5,648,350; No. 5,855,884; No. 5,821,259; No. 5,994,357; No. 6,624,148; No. 6,689,748; No. 6,984,667; No. 7,115,278 and pending US patent application No. 10/811,826, as well as EPO patent No. 1365777, covering the role of mast cells in the diseases discussed herein.

Immunological Reviews 2007

Vol. 217: 65–78

Printed in Singapore. All rights reserved

© 2007 The Authors
Journal compilation © 2007 Blackwell Munksgaard
Immunological Reviews
0105-2896

Differential release of mast cell mediators and the pathogenesis of inflammation

Summary: Mast cells are well known for their involvement in allergic and anaphylactic reactions, during which immunoglobulin E (IgE) receptor (FcεRI) aggregation leads to exocytosis of the content of secretory granules (1000 nm), commonly known as degranulation, and secretion of multiple mediators. Recent findings implicate mast cells also in inflammatory diseases, such as multiple sclerosis, where mast cells appear to be intact by light microscopy. Mast cells can be activated by bacterial or viral antigens, cytokines, growth factors, and hormones, leading to differential release of distinct mediators without degranulation. This process appears to involve *de novo* synthesis of mediators, such as interleukin-6 and vascular endothelial growth factor, with release through secretory vesicles (50 nm), similar to those in synaptic transmission. Moreover, the signal transduction steps necessary for this process appear to be largely distinct from those known in FcεRI-dependent degranulation. How these differential mast cell responses are controlled is still unresolved. No clinically available pharmacological agents can inhibit either degranulation or mast cell mediator release. Understanding this process could help develop mast cell inhibitors of selective mediator release with novel therapeutic applications.

Keywords: brain, inflammation, mast cells, multiple sclerosis, stress, vascular permeability

Introduction

Mast cells derive from a distinct precursor in the bone marrow (1, 2) and mature under the influence of stem cell factor (SCF) and various cytokines (3). Depending on their location or stage of maturation, mast cells express different amounts of surface antigens, some of which are involved in activation and others in cell recognition (4). Mast cells also express numerous chemokine receptors that do not induce degranulation but could render them susceptible to human immunodeficiency virus infection (5). SCF or c-kit ligand also acts as a mast cell chemoattractant, in addition to nerve growth factor (NGF) (6), monocyte chemoattractant protein-1 (MCP-1), and a molecule called 'regulated upon activation, normal T-cell expressed and secreted' (RANTES) (7). Mast cells are necessary for the development of allergic reactions, through cross-linking of their high-affinity surface receptors for immunoglobulin (Ig) E (FcεRI) (8), leading to degranulation and the release of vasoactive, proinflammatory, and nociceptive mediators; these include histamine, interleukin (IL)-6, IL-8, IL-13, prostaglandin D₂, leukotriene C₄ (LTC₄), tumor necrosis factor-α (TNF-α),

tryptase, and vascular endothelial growth factor (VEGF) (3, 9, 10) (Table 1). SCF enhances FcεRI-induced degranulation and cytokine production, although it does not induce degranulation on its own (11).

The types of cytokines produced are not fixed. For instance, human umbilical cord-blood-derived mast cells (hCBMCs) primed with IL-5 released fivefold higher levels of TNF-α, IL-5, macrophage inflammatory protein-1α (MIP-1α), and granulocyte-macrophage colony-stimulating factor (GM-CSF); unlike IL-4, IL-5 did not enhance FcεRI-dependent histamine release

(12). IL-4 enhances SCF-dependent mast cell proliferation and shifts IgE-dependent cytokine production in mature human mast cells to increased release of T-helper 2 cell (Th2) cytokines such as IL-3, IL-5, and IL-13 but not IL-6 expression (13). Mast cells in the presence of SCF produce predominantly proinflammatory cytokines, whereas in the presence of SCF and IL-4, also produce Th2 cytokines (14).

In addition to allergic triggers, mast cells can be activated by adenosine, anaphylatoxins, antibody light chains, bacterial and viral antigens, cytokines, endothelin, and neuropeptides (15).

Table 1. Mast cell mediators

| Mediators | Major pathophysiologic effects |
|---|--|
| Prestored | |
| Biogenic amines* | |
| Histamine | Vasodilation, angiogenesis, mitogenesis, suppressor T-cell activation |
| 5-Hydroxytryptamine (5-HT, serotonin) | Leukocyte regulation, vasoconstriction, pain |
| Chemokines | |
| IL-8, MCP-1, MCP-3, MCP-4, RANTES | Chemoattraction and tissue infiltration of leukocytes |
| Enzymes | |
| Arylsulfatases | Lipid/proteoglycan hydrolysis |
| Carboxypeptidase A | Peptide processing |
| Pro-caspase 3, 4 | Peptide processing |
| Chymase | Tissue damage, pain, angiotensin II synthesis |
| β-Hexosaminidase | Carbohydrate processing |
| Kinogenases | Synthesis of kinins, pain |
| Metalloproteinases | Tissue damage |
| Nitric oxide synthase | NO production |
| Peroxidases | Free oxygen radical production |
| Phospholipases | Arachidonic acid generation, inflammation |
| Tryptase | Activation of PAR, inflammation, pain, tissue damage, degradation of antigens and peptides |
| Polypeptides | |
| CRH | Inflammation, vasodilation, mast cell VEGF release |
| Endorphins | Analgesia, modulation of leukocyte activity |
| Endothelin | Sepsis |
| Kinins (bradykinin) | Inflammation, pain, vasodilation, mast cell trigger |
| Somatostatin (SRIF) | Anti-inflammatory (?), mast cell trigger |
| Substance P (SP) | Inflammation, pain, mast cell trigger |
| Urocortin (Ucn) | Inflammation, vasodilation, mast cell activation |
| VEGF | Neovascularization, vasodilation |
| Vasoactive intestinal peptide | Vasodilation, mast cell trigger |
| Proteoglycans | |
| Chondroitin sulfate | Connective tissue component, anti-inflammatory, mast cell inhibitor |
| Heparin | Angiogenesis, NGF stabilization, mast cell inhibitor |
| Hyaluronic acid | Connective tissue, component |
| De novo synthesized | |
| Cytokines | |
| IL-1, -3, -4, -5, -6, -9, -10, -13, -16 | Inflammation, leukocyte migration, pain |
| IFN-γ, MIF, TNF-α | Inflammation, leukocyte proliferation/activation |
| Growth Factors | |
| SCF, GM-CSF, GnRH-I b-FGF, NGF, VEGF | Growth of a variety of cells, mast cell proliferation |
| Phospholipid metabolites | |
| LTB ₄ | Leukocyte chemotaxis |
| LTC ₄ | Vasoconstriction, pain |
| PAF | Platelet activation, vasodilation, inflammation |
| PGD ₂ | Bronchoconstriction, pain |
| NO | Vasodilation, neuromodulation |

β-FGF, fibroblast growth factor; GnRH, gonadotropin-releasing hormone-I; LTB₄, leukotriene B₄; MIF, macrophage inflammatory factor; NO, nitric oxide; PAF, platelet-activating factor; PGD₂, prostaglandin D₂; SRIF, somatostatin release inhibitory factor, somatostatin; TGF-β, transforming growth factor-β.
*Mast cell can take up biogenic amines, store them, and secrete them.

Simultaneous addition of C3a and IgG led to increased degranulation of human mast cells (16). Monomeric IgE has been shown to reduce histamine, LTC, and IL-8 and maintain histamine release from human cultured lung mast cells (17). Ig-free light chains can also elicit immediate hypersensitivity-like responses (18, 19) with subsequent T-cell-mediated immune responses (20). The anti-bacterial peptides, human β -defensins, can reunite mast cells and induce degranulation (21). Consequently, mast cells could play an important role in innate or acquired immunity (3, 22, 23) as well as limit endothelin-related toxicity during bacterial infections (24). Increasing evidence also indicates that mast cells are critical for the pathogenesis of a number of inflammatory diseases (Table 2), but this role could only be achieved if mast cells could release selective mediators without degranulation (Fig. 1) that would otherwise lead to allergic or anaphylactic reactions (15).

Mast cells are also known to infiltrate a number of tumors, but they appear intact with light microscopy and are considered to induce angiogenesis and provide an environment conducive to cancer growth (25–28). Angiogenesis in endometrial cancer increases with tumor progression, and angiogenic tryptase secreted by host mast cells cooperates in this induction (29).

Differential release of mast cell mediators

Mast cells are ubiquitous in the body, including the brain where they do not express Fc ϵ RI protein under normal conditions

Table 2. Inflammatory diseases involving and mast cell activation

| Disease | Major pathophysiologic role |
|----------------------------|--|
| Asthma | Bronchoconstriction, pulmonary inflammation |
| Atopic dermatitis | Skin vasodilation, T-cell recruitment, inflammation, itching |
| Coronary artery disease | Coronary inflammation, myocardial ischemia |
| Chronic fatigue syndrome | Brain inflammation, exhaustion |
| Chronic prostatitis | Prostate inflammation, pain |
| Fibromyalgia | Muscle inflammation, pain |
| Inflammatory bowel disease | Gastrointestinal inflammation, pain |
| Interstitial cystitis | Bladder mucosal damage, inflammation, pain |
| Migraines | Meningeal vasodilation, inflammation, pain |
| Multiple sclerosis | Increased BBB permeability, brain inflammation, demyelination, T-cell activation |
| Neurofibromatosis | Skin nerve growth, fibrosis |
| Osteoarthritis | Articular erosion, inflammation, pain |
| Psoriasis | Skin inflammation, T-cell recruitment |
| Rheumatoid arthritis | Joint inflammation, cartilage erosion |
| Rhinosinusitis | Nasal and sinus inflammation |

(30), not surprising as the brain is not known to develop allergic reactions and as IgE does not cross the blood–brain barrier (BBB). Moreover, mast cells are rarely seen to degranulate during autoimmune (31) or inflammatory processes (32). The only way to explain how this versatile cell may regulate immune responses or how it could be involved in inflammatory diseases without causing anaphylactic shock is through ‘differential’ or ‘selective’ release of mediators (33) without degranulation (34, 35).

Mast cells could release the content of individual granules (36) that may contain different mediators at different locations. A number of innate and exogenous molecules can trigger mast cells to release key mediators differentially or selectively (34, 35, 37) (Table 3). This process was originally reported for serotonin, which could be released without histamine (33). Serotonin could also be released without arachidonic acid metabolites (38–40). Differential release of eicosanoids was also reported without histamine (39). Others also showed differential release of IL-6 in response to bacterial lipopolysaccharide (LPS), in the presence of the phosphatidylinositol 3-kinase (PI3K) inhibitor wortmannin, or triggered by SCF (41–44). IL-1 can also stimulate human mast cells to release IL-6 selectively (45). Recently, corticotropin-releasing hormone (CRH) was shown to stimulate selective release of VEGF without degranulation and histamine or tryptase release from the human mast cell line (HMC-1) and hCBMCs (46). Prostaglandin E₂ (PGE₂) also induced selective VEGF release (47) as well as release of MCP-1 without degranulation (48). Yet, PGE₂ inhibited Fc ϵ RI-induced histamine release from human lung mast cells (49). Strangely, PGE₂ stimulated skin mast cell degranulation in older but not in younger mice (50). Stromal-cell-derived factor-1 α can selectively produce IL-8 from human mast cells also without degranulation (51). Activation of human cultured mast cells by CD40 ligand was recently shown to lead to release of the chemokines IL-8 and MIP-1 without degranulation (52). Interestingly, nanoreceptor-type protein kinase-deficient mast cells could not generate IL-6, TNF, or MCP-1 during Fc ϵ RI aggregation, but IL-13 production was intact, suggesting divergent regulatory pathways (53).

Toll-like receptors (TLRs) are critical in innate and acquired immunity (54–56). Rodent mast cells express TLR4, which binds LPS and induces the release of TNF- α without degranulation, while peptidoglycan induces degranulation and histamine release through TLR2 (57, 58). LPS also induced secretion of IL-5, IL-10, and IL-13 but not GM-CSF, IL-1, or LTC₄ (58, 59). Activation of TLRs appears to be even more complicated, as LPS produced TNF- α , IL-1, IL-6, and IL-13 but not IL-4 or IL-5, while TLR2 activation produced IL-4, IL-6, and




Fig. 1. Schematic representation of some of the triggers permitting differential release of mast cell mediators and their contribution to inflammation. M, macrophages; T, T cells.

IL-13 but not IL-1 (60). Antigen apparently could have a synergistic action with TLR2 and TLR4 in enhancing cytokine production from rodent mast cells (61).

Fetal rat-skin-derived mast cells express viral TLR3, TLR7, and TLR9, and activation by polyoligodeoxynucleotide and CpG induced release of TNF- α , IL-6, RANTES, and MIP, again without degranulation (62). Human mast cells can produce IL-6 through viral TLR9 activation (63), while they produce interferon (IFN) in response to double-stranded RNA through TLR3 (64). We showed that HMC-1 expresses TLR3, TLR5, TLR7, and TLR9 and that TLR9 expression was increased in response to its activation (65). No specific ultrastructural or biochemical events have so far been defined in TLR-induced release of cytokines, although they may be able to predispose or enhance allergic responses. These results suggest that bacterial or viral infections could lead to aberrant inflammatory responses through mast cell activation without systemic signs of allergy.

Low-intensity stimulation of Fc ϵ RI with IgE plus anti-IgE or IgE plus low antigen positively regulates degranulation and cytokine production, whereas Lyn (an sarcoma inducing gene of rous sarcoma virus (Src) family kinase) works as a negative regulator of high-intensity stimulation with IgE plus high antigen (66). However, Lyn^{-/-} mice had increased Fc ϵ RI expression, circulating histamine, and eosinophilia (67). Suboptimal antigen challenge of human mast cells led to Fc ϵ RI unresponsiveness that correlated to reduced spleen tyrosine kinase (Syk) levels (68). Suboptimal IgE concentrations could induce actin assembly that blocked degranulation (69). However, low antigen still permitted MCP-1 release (70).

Mizolastine, a histamine-1 receptor antagonist, inhibits LTC₄ synthesis in human mast cells and basophils, but it enhances histamine and IL-4 release only from anti-IgE-stimulated basophils (71). LPS enhances production of IL-9 and IL-13 but not IL-4 from primary murine bone-marrow-derived mast cells activated with ionomycin or IgG-antigen (72). IL-4 enhances

Table 3. Examples of differential release of mast cell mediators

| Stimuli | Mast cell type used | Mediators released | Mediators not released | Physiological importance | References |
|---|---------------------|---|---|---------------------------------|---------------------------------------|
| Endogenous | | | | | |
| CD4 ligands | hCBMC | IL-8, MCP-1 | Histamine | Leukocyte chemotaxis | Fischer <i>et al.</i> (52) |
| CD8 ligands | RPMC | TNF- α , NO | Histamine | T-cell interactions | Lin <i>et al.</i> (185) |
| CRHR-1 | hCBMC | VEGF | H, tryptase, IL-8 | Inflammation | Cao <i>et al.</i> (144) |
| CRHR-2 | hCBMC | IL-6 | H, tryptase, IL-8, VEGF | Inflammation | Papadopoulou <i>et al.</i> (186) |
| Endothelin-1-3 | RMMC | TNF- α , IL-12 \uparrow * | IL-4, IL-10, IL-13 \downarrow * | Th1 immunity | Coulombe <i>et al.</i> (187) |
| IL-1 | hCBMC | IL-6, IL-8, TNF | H, tryptase | Inflammation | Kandere-Grzybowska <i>et al.</i> (45) |
| IL-1 β | RPMC | NO | PAF, H | Inflammation | Hogaboam <i>et al.</i> (188) |
| IL-12 | RPMC | IFN- γ | Histamine | Th1 immunity | Gupta <i>et al.</i> (189) |
| LTC ₄ /LTD ₄ | IL-4-primed hCBMC | TNF- α , MIP-1 α , IL-5 | H | Inflammation | Mellor <i>et al.</i> (190) |
| Monomeric IgE | BMMC | IL-6 | H, LTC ₄ | Mast cell survival | Kalesnikoff <i>et al.</i> (191) |
| PGE ₂ | RPMC | IL-6 | H, TNF- α | Inflammation | Leal-Berumen <i>et al.</i> (192) |
| PGE ₂ | hCBMC | MCP-1 | No degranulation | Angiogenesis | Nakayama <i>et al.</i> (48) |
| SCF | BMMC | IL-6 | H, LTC ₄ , TNF- α | Mast cell development | Gagari <i>et al.</i> (43) |
| SDF- α | hCBMC | IL-8 | H, GM-CSF, IFN- γ , IL-1 β | Endothelial transmigration | Lin <i>et al.</i> (51) |
| Suboptimal Fc ϵ RI stimulation | BMMC | MCP-1, H low | IL-10, H | Chemokines >>> Cytokines /HA | Gonzalez-Espinosa <i>et al.</i> (70) |
| Thrombin | BMMC | IL-6 | 5-HT, TNF- α | Coronary inflammation | Gordon <i>et al.</i> (193) |
| Exogenous | | | | | |
| Amisriptyline | RPMC | Serotonin | Histamine | Headaches | Theoharides <i>et al.</i> (33) |
| Cholera toxin | RPMC | IL-6 | TNF- α | Inflammation | Leal-Berumen <i>et al.</i> (194) |
| CpG DNA | BMMC | TNF- α , IL-6 | H, IL-4, IL-12, GM-CSF, IFN- γ | Host response to bacteria | |
| <i>Helicobacter pylori</i> VacA toxin | BMMC | IL-6, IL-8, TNF | H | Gastric injury | Supajatura <i>et al.</i> (60) |
| LPS | RPMC | IL-6 | H | Bacterial infection | Leal-Berumen <i>et al.</i> (41) |
| PMA | BMMC | VPF/VEGF | 5-HT | Angiogenesis | Boesiger <i>et al.</i> (10) |
| Peptidoglycan | hCBMC | GM-CSF, IL-1 β , RANTES, LTC ₄ | β -hexosaminidase, IL-6 | Exacerbation of asthma | McCurdy <i>et al.</i> (58) |

BMMC, bone marrow-derived mast cells (rodent); CRH, corticotropin releasing hormone; GM-CSF, granulocyte-macrophage-colony stimulating factor; H, histamine; 5-HT; 5-hydroxytryptamine; LPS, lipopolysaccharid; LTD₄, leukotriene D₄; RPMC, rat peritoneal mast cells; PMA, phorbol myristate acetate; SCF, stem cell factor; SDF, stromal cell-derived factor; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor; VPF, vascular permeability factor.

whereas INF- γ inhibits the Fc ϵ RI-mediated production of MIP-1 α , IL-8, and GM-CSF from human mast cells (73). B-cell lymphoma 10 (Bcl10) and mucosal-associated lymphoid tissue-1 (MALT-1) are identified as a key regulators of mast cell signaling. Mice deficient for either protein show severely impaired IgE-dependent late-phase anaphylactic reactions. Mast cells from these animals neither activate NF- κ B nor produce TNF- α or IL-6 upon Fc ϵ RI signaling, while degranulation and LT secretion are normal. Thus, Bcl10 and MALT-1 are essential positive mediators of Fc ϵ RI-dependent mast cell activation that selectively uncouple NF- κ B-induced proinflammatory cytokine production from degranulation and LT synthesis (74).

Mechanisms involved

Fc ϵ RI-induced mast cell degranulation requires calcium-independent granule translocation to the surface but calcium-

dependent exocytosis (75). This process involved SNAP-23 phosphorylation (76). Mast cells can undergo ultrastructural alterations of their electron-dense granular core indicative of secretion but without degranulation, a process that has been termed 'activation' (77–79), 'intragranular activation' (80), or 'piecemeal' degranulation (81) (Fig. 2). Piecemeal degranulation was recently shown to involve vesicular transport of secretory granules contents (82). However, these ultrastructural observations have not been linked to release of a specific mediator. We had shown that differential release of serotonin involved its being sequestered from secretory granules inside vesicles containing high-affinity serotonin-binding proteins from which it was then released (83). More recently, we showed that IL-6 release in response to IL-1 involves 40–80 nm vesicles unrelated to the secretory granules (800–1000 nm), and IL-4 release from these vesicles did not require extracellular calcium ions (45). Selective mediator segregation in and release




Fig. 2. Mast cells in inflammatory diseases.

(A) Degranulated human LAD2 cell in response to 0.01 mM MBP. (B) Activated bladder mast cell from a patient with the inflammatory disease interstitial cystitis. (C) An activated brain mast cell from monkey EAE, with prominent intragranular changes. (D) Section of one hCBMC after cryoimmunoelectron microscopy showing a vesicle (arrow) releasing a group of gold-labeled antibody-recognized selectively release IL-6 molecules in response to IL-1 (100 nM).

from specific vesicles could be accomplished through corresponding 'non-functional' receptors expressed on such vesicles, as shown for eosinophils (84).

The downstream pathway steps involved in FcεRI-induced or peptide-induced degranulation are well known and appear to be distinct from those necessary in differential secretion (Table 4). For instance, FcεRI aggregation requires extracellular calcium ions as well as PI3K, extracellular-signal-regulated kinase, c-Jun N-terminal kinase (JNK), NF-κB, and protein kinase C (PKC) activation, although PKC isozyme-ε was recently shown to be redundant (85, 86). FcεRI aggregation leads to production of phosphatidylinositol-3,4,5-triphosphate through the action of PI3K, which is inhibited by phosphatase and the molecule called 'tensin homologue deleted on chromosome ten' (PTEN); PTEN knockdown induced constitutive cytokine production without degranulation along with phosphorylation of AKT, p38 mitogen-activated protein kinase (MAPK) and JNK (87). Secretion in response to NGF appears to be regulated by tyrosine kinase (TK), PI3K, and PKC, but not MAPK, while secretion by compound 48/80 requires PLC, TK, MAPK, and PKC (88). In contrast, IL-1 stimulation of mast cells was extracellular calcium independent and involved p38 MAPK, NF-κB, and PKCθ isozyme activation (89). CRH activation of selective mast cell VEGF release was also extracellular calcium independent but

involved only protein kinase A (PKA) and p38 MAPK activation (46). Adapter complexes appear to segregate FcεRI-dependent activation of mast cells; for instance, the Bcl10-MALT-1 complex permits IL-6 and TNF-α release without degranulation (90).

Gene array analysis of human mast cells activated by IgE showed overexpression of numerous, mostly inflammation-related genes (91). In contrast, among the genes that were upregulated more than 1.5-fold after CRH stimulation (6 h) were those related to vesicular trafficking and release (Table 5) (unpublished data).

Multiple sclerosis

One disease where mast cells have been implicated without degranulation is multiple sclerosis (MS), a demyelinating condition (92, 93) involving brain infiltration by lymphocytes (94, 95). The role of CD4⁺ T cells is well documented in MS, but this CD4⁺ Th1 model has recently been questioned (96). Increasing evidence implicates Th2 processes typically associated with allergic reactions (97–99). For instance, myelin basic protein (MBP) induced homogeneous mast cell activation and brain demyelination (100). Virally induced encephalomyelitis could not develop in W/W^v mast-cell-deficient mice (101, 102), and experimental allergic encephalomyelitis (EAE) was

Table 4. Signaling steps involved in mast cell degranulation and differential secretion

| Steps involved | Triggers | | | | |
|--------------------|----------|--------------------|-------|-----|------|
| | FcεRI | NGF | 48/80 | CRH | IL-1 |
| Ca ²⁺ * | + | + | – | – | – |
| PI3K | + | + | – | ? | ? |
| PKA | – | – | – | + | – |
| TK | + | + | + | – | – |
| p38/MARK | –/+ | – | – | + | + |
| ERK1/2 | + | ? | ? | – | – |
| JNK1/2 | + | ? | ? | – | – |
| NF-κB | + | + | + | – | + |
| PKC isoforms | + | (α, β, δ, ε, θ, μ) | + | – | ? |
| | | | | | + |

ERK, extracellular signal-regulated protein kinase; PKA, protein kinase A.
*Extracellular.

attenuated and delayed in these mice (103). Subsequent studies suggested that the inability of mast-cell-deficient mice to fully develop EAE may also depend on reduced T-cell activation (104, 105). Ig-free light chains can sensitize mast cell release of cytokines that induce T-cell-mediated immune reactions critical in MS (20). Mast cell contact with activated T cells leads to secretion of matrix metalloproteinase-9 and IL-6 from human mast cells (106). Moreover, mast cells can promote IgE-dependent and T-cell-independent proliferation and activation through TNF-α release (107). We recently showed that mast cell contact with activated T cells stimulates the latter to produce 30-fold more IL-2, which is further increased when mast cells are activated by MBP (108).

Mast cells could, therefore, participate in the pathogenesis of MS in different ways (Table 6). They could be activated by bacterial or viral antigens and release cytokines/chemokines, selectively inducing T-cell/macrophage recruitment and activation. Myelin damage could then release fragments and other

Table 5. Secretion-related genes upregulated during CRH activation of HMC-1 cells*

| Code | Gene name | Fold increase |
|----------|--|---------------|
| SPIR-1 | Spir-1 protein | 23.60 |
| CDC42BPB | CDC42-binding protein kinase β (DMPK-like) | 12.65 |
| PCANAP7 | Synaptotagmin VII | 7.20 |
| MTMR7 | Myotubularin-related protein 7 | 5.15 |
| SYNGR2 | Synaptogyrin 2 | 4.70 |
| STX18 | Syntaxin 18 | 2.34 |
| SYN | Synaptophysin | 2.30 |
| PCLO | Piccolo | 1.93 |
| RAB3A | RAB3A, RAS oncogene family member | 1.80 |
| STX1B2 | Syntaxin 1B2 | 1.76 |
| STXBP6 | Syntaxin-binding protein 6 (amisyn) | 1.70 |

*Our unpublished results. DMPK, dystrophy protein kinase.

Table 6. Possible mast cell actions in MS

- Adhesion molecule induction
- BBB disruption
- Demyelination
- Fibrosis and plaque formation
- Macrophage recruitment
- PAR-related inflammation
- T-cell activation
- T-cell infiltration

neuropeptides that could stimulate degranulation and release of the protease tryptase, which could in turn enhance demyelination and inflammation through stimulation of protease activated receptor-2 (PAR-2) (Fig. 1).

Affected brains in MS areas fill with fibrotic tissue forming the MS plaque (109) that also contains activated mast cells (110–112). Gene array analysis of MS plaques showed overexpression of genes for FcεRI, the histamine-1 receptor, and tryptase, all of which are associated with mast cells (113–115). Mast cell tryptase is increased in the cerebrospinal fluid (CSF) of patients with MS (116), can activate peripheral mononuclear cells to secrete TNF and IL-6 (117), and stimulate PARs that can lead to microvascular leakage and widespread inflammation (118–121).

BBB breakdown (122) precedes any pathological or clinical signs of MS (112, 123, 124), as shown by trans-BBB leakage of albumin (125) and magnetic resonance imaging-gadolinium studies (124). Mast cells have been proposed as the ‘immune gate to the brain’ (126). They line the BBB (77) and are activated in EAE, but they show ultrastructural signs of activation without typical degranulation (127) (Fig. 2). Mast cells migrate from the meninges (128) and from blood to brain (129). Mast-cell-derived products can enter neurons, a process termed transgranulation, indicating a novel form of brain-immune system communication (130). Brain mast cells could be activated by non-allergic stimulation, such as myelin basic protein (MBP) (100), as well as by acute stress (131). Restraint stress activated brain mast cells and led to CSF elevation of rat mast cell protease I (132), effects abolished by polyclonal anti-serum to CRH (132) and the CRH receptor-1 (CRHR1) antagonist antalarmin (132, 133). Acute stress also increased BBB permeability through the action of CRH (134) on brain mast cells (134, 135). Acute restraint stress also shortened the time required for the development of EAE in mice and increased BBB permeability (136). CRH^{-/-} mice with EAE were shown recently to have decreased clinical disability and decreased brain infiltration by immune cells (137). Restraint stress was also reported to increase mortality rates and lead to higher central nervous system viral load during Theiler’s virus infection (138). Stressed mice had increased inflammatory lesions in spinal cord

and developed autoimmune antibodies to MBP (139). Acute restraint stress (140) as well as CRH (141) and its structurally related peptide, urocortin (142), can activate mast cells and induce mast-cell-dependent vascular permeability in rodent as well as in human skin (143), another neuroectodermal tissue. We recently showed that human mast cells express CRHR, activation of which leads to selective release of VEGF (144). The frequency, chronicity, severity, and timing of stressors appear to be important (145).

The effect of stress and CRH on mast cell activation and BBB permeability may help explain clinical findings in patients with MS. The symptoms of MS and the appearance of new lesions have been repeatedly shown to be precipitated by psychological stress (109, 146–151). In one study in Denmark (151), parents who had unexpectedly lost a young child had a significantly increased risk of MS compared with other bereaved parents. Meta-analysis of 14 prospective studies showed a significantly increased risk of MS exacerbations after stressful events (152). The role of ‘stress-response systems for the pathogenesis and progression of MS’ was reviewed recently, and it was proposed that MS is associated with glucocorticoid-insensitive immune cells (153). Such a finding has never been documented. An experimental study argued that stress does not affect MS because the function of peripheral blood leukocytes in patients with MS is apparently unaffected by stress (154). However, this reasoning is faulty, as stress may predominantly affect mast cells and T cells but not peripheral leukocytes. In fact, restraint stress induced mast-cell-dependent increase in mouse serum IL-6 levels (155), while examination stress dramatically increased serum TNF- α levels in medical student volunteers (156). These

results suggest that mast-cell-derived cytokines in response to stress, or other triggers, may be involved in MS exacerbations.

Inhibition

There is still no curative therapy for MS (157). Mast cells were considered a therapeutic target for MS (158). Unfortunately, very few clinically available drugs can inhibit mast cell secretion. Disodium cromoglycate (cromolyn) was originally shown to inhibit rodent mast cells (159, 160), but it has proven ineffective in human mast cells (161). Chondroitin sulfate, the major constituent of mast cell granules (161), and the flavonoid quercetin (162, 163) are potent mast cell inhibitors. Moreover, quercetin is the only compound shown to inhibit differential release of IL-6 in response to IL-1 by reducing intracellular calcium ions and PKC θ phosphorylation (89). Flavonoids may also inhibit mast cell degranulation through inhibition of the intracellular activation of Syk (164). Flavonoids may also be acting as a 78-kDa protein (165) shown to mediate the inhibitory effect of cromolyn on rat mast cells (160) and found to be homologous to moesin (166). The inhibitory receptor IRp60 (CD300a) was shown to be expressed in human cord blood mast cells, and its neutralization in mice led to increased mediators (167). Human mast cells also express the myeloid cell inhibitory receptor CD200, engagement of which inhibited Fc ϵ RI-induced phosphorylation activation (168). Two peptides derived from complement component C3a, C3a⁺, and C3a9 were shown to inhibit Fc ϵ RI-induced degranulation and TNF- α release (169). Degranulation in response to Fc ϵ RI aggregation or compound 48/80 was




Fig. 3. Summary scheme showing morphological appearances at the ultrastructural level of rat peritoneal mast cells, along with potential triggers and proposed pathophysiologic functions. Intact (center), exocytotic degranulation (left), and intragranular changes (right).

severely impaired in IL-2-inducible T-cell kinase-1 mice (170). Nitric oxide also blocked FcεRI-induced IL-4 and IL-6 production through TNF-α inhibition of Jun (171).

It is of interest that flavonoids known to inhibit mast cell secretion have also been shown to inhibit macrophage myelin phagocytosis (172) and EAE (173, 174). The flavone luteolin was also a strong inhibitor of human autoimmune T cells (175), and we showed that luteolin can inhibit mast cell activation and mast cell-dependent T-cell activation (108).

Conclusion

Mast cells are unique immune cells that can be activated by numerous triggers, including CRH (176). The versatile roles of

mast cells, especially in the brain, must utilize the mast cell's ability to secrete specific mediators selectively without degranulation. Differential or selective release of mast cell mediators without degranulation has been stressed repeatedly as critical in the pathogenesis of inflammatory diseases (15, 177), atopic dermatitis and psoriasis (178), chronic fatigue syndrome (179), cancer (26), coronary artery disease (177), fibromyalgia (180), inflammatory arthritis (181), interstitial cystitis (182, 183), migraines (184), and MS (15, 131, 158) (Fig. 3). Understanding the mechanism of differential release could permit us to selectively inhibit mast cell involvement in pathological inflammatory conditions, while permitting their function in innate or acquired immunity.

References

- Rodewald HR, Dessing M, Dvorak AM, Galli SJ. Identification of a committed precursor for the mast cell lineage. *Science* 1996;**271**:818–822.
- Chen CC, Grimbaldston MA, Tsai M, Weissman IL, Galli SJ. Identification of mast cell progenitors in adult mice. *Proc Natl Acad Sci USA* 2005;**102**:11408–11413.
- Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. *Nat Immunol* 2005;**6**:135–142.
- Valent P, et al. Variable expression of activation-linked surface antigens on human mast cells in health and disease. *Immunol Rev* 2001;**179**:74–81.
- Juremalm N, Nilsson G. Chemokine receptor expression by mast cells. *Chem Immunol Allergy* 2005;**87**:130–144.
- Aloe L, Levi-Montalcini R. Mast cells increase in tissues of neonatal rats injected with the nerve growth factor. *Brain Res* 1977;**133**:358–366.
- Conti P, et al. Impact of Rantes and MCP-1 chemokines on *in vivo* basophilic mast cell recruitment in rat skin injection model and their role in modifying the protein and mRNA levels for histidine decarboxylase. *Blood* 1997;**89**:4120–4127.
- Blank U, Rivera J. The ins and outs of IgE-dependent mast-cell exocytosis. *Trends Immunol* 2004;**25**:266–273.
- Grutzkau A, et al. Synthesis, storage and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF₂₀₆. *Mol Biol Cell* 1998;**9**:875–884.
- Boesiger J, et al. Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of Fcε receptor I expression. *J Exp Med* 1998;**188**:1135–1145.
- Hundley TR, Gilfillan AM, Tkaczyk C, Andrade MV, Metcalfe DD, Beaven MA. Kit and FcεRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells. *Blood* 2004;**104**:2410–2417.
- Ochi H, DeJesus NH, Hsieh FH, Austen KF, Boyce JA. IL-4 and -5 prime human mast cells for different profiles of IgE-dependent cytokine production. *Proc Natl Acad Sci USA* 2000;**97**:10509–10513.
- Lorentz A, et al. IL-4-induced priming of human intestinal mast cells for enhanced survival and Th2 cytokine generation is reversible and associated with increased activity of ERK1/2 and c-Fos. *J Immunol* 2005;**174**:6751–6756.
- Bischoff SC, Sellge G, Manns MP, Lorentz A. Interleukin-4 induces a switch of human intestinal mast cells from proinflammatory cells to Th2-type cells. *Int Arch Allergy Immunol* 2001;**124**:151–154.
- Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. *J Neuroimmunol* 2004;**146**:1–12.
- Woolhiser MR, Brockow K, Metcalfe DD. Activation of human mast cells by aggregated IgG through FcγRI: additive effects of C3a. *Clin Immunol* 2004;**110**:172–180.
- Cruse G, Kaur D, Yang W, Duffy SM, Brightling CE, Bradding P. Activation of human lung mast cells by monomeric immunoglobulin E. *Eur Respir J* 2005;**25**:858–863.
- Kraneveld AD, et al. Elicitation of allergic asthma by immunoglobulin free light chains. *Proc Natl Acad Sci USA* 2005;**102**:1578–1583.
- Redegeld FA, et al. Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses. *Nat Med* 2002;**8**:694–701.
- Redegeld FA, Nijkamp FP. Immunoglobulin free light chains and mast cells: pivotal role in T-cell-mediated immune reactions? *Trends Immunol* 2003;**24**:181–185.
- van Ophoven A, Hertle L. Long-term results of amitriptyline treatment for interstitial cystitis. *J Urol* 2005;**174**:1837–1840.
- Rottem M, Mekori YA. Mast cells and autoimmunity. *Autoimmun Rev* 2005;**4**:21–27.
- Galli SJ, Kalesnikoff J, Grimbaldston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as “tunable” effector and immunoregulatory cells: recent advances. *Annu Rev Immunol* 2005;**23**:749–786.
- Maurer M, et al. Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. *Nature* 2004;**432**:512–516.
- Norrbj K. Mast cells and angiogenesis. *APMIS* 2002;**110**:355–371.
- Theoharides TC, Conti P. Mast cells: the Jekyll and Hyde of tumor growth. *Trends Immunol* 2004;**25**:235–241.
- Ribatti D, Crivellato E, Roccaro AM, Ria R, Vacca A. Mast cell contribution to angiogenesis related to tumour progression. *Clin Exp Allergy* 2004;**34**:1660–1664.
- Feoktistov I, Ryzhov S, Goldstein AE, Biaggioni I. Mast cell-mediated stimulation of angiogenesis: cooperative interaction between A2B and A3 adenosine receptors. *Circ Res* 2003;**92**:485–492.
- Ribatti D, et al. Neovascularization and mast cells with tryptase activity increase simultaneously with pathologic progression in human endometrial cancer. *Am J Obstet Gynecol* 2005;**193**:1961–1965.
- Pang X, Letourneau R, Rozniecki JJ, Wang L, Theoharides TC. Definitive characterization of rat hypothalamic mast cells. *Neuroscience* 1996;**73**:889–902.

31. Benoist C, Mathis D. Mast cells in autoimmune disease. *Nature* 2002;**420**:875–878.
32. Woolley DE. The mast cell in inflammatory arthritis. *N Engl J Med* 2003;**348**:1709–1711.
33. Theoharides TC, Bondy PK, Tsakalos ND, Askenase PW. Differential release of serotonin and histamine from mast cells. *Nature* 1982;**297**:229–231.
34. Kops SK, Theoharides TC, Cronin CT, Kashgarian MG, Askenase PW. Ultrastructural characteristics of rat peritoneal mast cells undergoing differential release of serotonin without histamine and without degranulation. *Cell Tissue Res* 1990;**262**:415–424.
35. Kops SK, Van Loveren H, Rosenstein RW, Ptak W, Askenase PW. Mast cell activation and vascular alterations in immediate hypersensitivity-like reactions induced by a T cell derived antigen-binding factor. *Lab Invest* 1984;**50**:421–434.
36. Theoharides TC, Douglas WW. Secretion in mast cells induced by calcium entrapped within phospholipid vesicles. *Science* 1978;**201**:1143–1145.
37. Van Loveren H, Kops SK, Askenase PW. Different mechanisms of release of vasoactive amines by mast cells occur in T cell-dependent compared to IgE-dependent cutaneous hypersensitivity responses. *Eur J Immunol* 1984;**14**:40–47.
38. Benyon R, Robinson C, Church MK. Differential release of histamine and eicosanoids from human skin mast cells activated by IgE-dependent and non-immunological stimuli. *Br J Pharmacol* 1989;**97**:898–904.
39. Levi-Schaffer F, Shalit M. Differential release of histamine and prostaglandin D₂ in rat peritoneal mast cells activated with peptides. *Int Arch Allergy Appl Immunol* 1989;**90**:352–357.
40. van Haaster CM, Engels W, Lemmens PJMR, Hornstra G, van der Vusse GJ, Heemskerk JWM. Differential release of histamine and prostaglandin D₂ in rat peritoneal mast cells: roles of cytosolic calcium and protein tyrosine kinases. *Biochim Biophys Acta* 1995;**1265**:79–88.
41. Leal-Berumen I, Conlon P, Marshall JS. IL-6 production by rat peritoneal mast cells is not necessarily preceded by histamine release and can be induced by bacterial lipopolysaccharide. *J Immunol* 1994;**152**:5468–5476.
42. Marquardt DL, Alongi JL, Walker LL. The phosphatidylinositol 3-kinase inhibitor wortmannin blocks mast cell exocytosis but not IL-6 production. *J Immunol* 1996;**156**:1942–1945.
43. Gagari E, Tsai M, Lantz CS, Fox LG, Galli SJ. Differential release of mast cell interleukin-6 via c-kit. *Blood* 1997;**89**:2654–2663.
44. Hojo H, et al. Differential production of interleukin-6 and its close relation to liver metastasis in clones from murine P815 mastocytoma. *Cancer Lett* 1996;**108**:55–59.
45. Kandere-Grzybowska K, et al. IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. *J Immunol* 2003;**171**:4830–4836.
46. Cao J, Curtis CL, Theoharides TC. Corticotropin-releasing hormone induces vascular endothelial growth factor release from human mast cells via the cAMP/protein kinase A/p38 mitogen-activated protein kinase pathway. *Mol Pharmacol* 2006;**69**:998–1006.
47. Abdel-Majid RM, Marshall JS. Prostaglandin E2 induces degranulation-independent production of vascular endothelial growth factor by human mast cells. *J Immunol* 2004;**172**:1227–1236.
48. Nakayama T, Mutsuga N, Yao L, Tosato G. Prostaglandin E2 promotes degranulation-independent release of MCP-1 from mast cells. *J Leukoc Biol* 2006;**79**:95–104.
49. Kay LJ, Yeo WW, Peachell PT. Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulation. *Br J Pharmacol* 2006;**147**:707–713.
50. Nguyen M, Pace AJ, Koller BH. Age-induced reprogramming of mast cell degranulation. *J Immunol* 2005;**175**:5701–5707.
51. Lin TJ, Issekutz TB, Marshall JS. Human mast cells transmigrate through human umbilical vein endothelial monolayers and selectively produce IL-8 in response to stromal cell-derived factor-1 alpha. *J Immunol* 2000;**165**:211–220.
52. Fischer M, et al. Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. *J Clin Invest* 2006;**116**:2748–2756.
53. Gomez G, et al. Impaired FcεpsilonRI-dependent gene expression and defective eicosanoid and cytokine production as a consequence of Fyn deficiency in mast cells. *J Immunol* 2005;**175**:7602–7610.
54. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. *Nat Immunol* 2001;**2**:675–680.
55. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. *Nature* 2000;**406**:782–787.
56. Heine H, Lien E. Toll-like receptors and their function in innate and adaptive immunity. *Int Arch Allergy Immunol* 2003;**130**:180–192.
57. Varadaradjalou S, et al. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. *Eur J Immunol* 2003;**33**:899–906.
58. McCurdy JD, Olynych TJ, Maher LH, Marshall JS. Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. *J Immunol* 2003;**170**:1625–1629.
59. Masuda A, Yoshikai Y, Aiba K, Matsuguchi T. Th2 cytokine production from mast cells is directly induced by lipopolysaccharide and distinctly regulated by c-Jun N-terminal kinase and p38 pathways. *J Immunol* 2002;**169**:3801–3810.
60. Supajatura V, et al. Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. *J Clin Invest* 2002;**109**:1351–1359.
61. Qiao H, Andrade MV, Lisboa FA, Morgan K, Beaven MA. FcεpsilonR1 and toll-like receptors mediate synergistic signals to markedly augment production of inflammatory cytokines in murine mast cells. *Blood* 2006;**107**:610–618.
62. Matsushima H, Yamada N, Matsue H, Shimada S. TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells. *J Immunol* 2004;**173**:531–541.
63. Ikeda RK, et al. Accumulation of peribronchial mast cells in a mouse model of ovalbumin allergen induced chronic airway inflammation: modulation by immunostimulatory DNA sequences. *J Immunol* 2003;**171**:4860–4867.
64. Kulka M, Alexopoulou L, Flavell RA, Metcalfe DD. Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3. *J Allergy Clin Immunol* 2004;**114**:174–182.
65. Hyde BB, Papadopoulou N, Theoharides TC. Human mast cells express TLR 3, 7&9, mRNA is induced by viral DNA sequence K3 CPG-ODN. *Proc Am Assoc Immunol* 2006 (Boston May 12-16); **176**:5322.
66. Xiao W, et al. Positive and negative regulation of mast cell activation by Lyn via the FcεpsilonRI. *J Immunol* 2005;**175**:6885–6892.
67. Odom S, et al. Negative regulation of immunoglobulin E-dependent allergic responses by Lyn kinase. *J Exp Med* 2004;**199**:1491–1502.
68. Kopley CL. Antigen-induced reduction in mast cell and basophil functional responses due to reduced Syk protein levels. *Int Arch Allergy Immunol* 2005;**138**:29–39.
69. Oka T, Hori M, Tanaka A, Matsuda H, Karaki H, Ozaki H. IgE alone-induced actin assembly modifies calcium signaling and degranulation in RBL-2H3 mast cells. *Am J Physiol Cell Physiol* 2004;**286**:C256–C263.

70. Gonzalez-Espinosa C, et al. Preferential signaling and induction of allergy-promoting lymphokines upon weak stimulation of the high affinity IgE receptor on mast cells. *J Exp Med* 2003;**197**:1453–1465.
71. Triggiani M, et al. Differential modulation of mediator release from human basophils and mast cells by mizolastine. *Clin Exp Allergy* 2004;**34**:241–249.
72. Stassen M, et al. IL-9 and IL-13 production by activated mast cells is strongly enhanced in the presence of lipopolysaccharide: NF-kappa B is decisively involved in the expression of IL-9. *J Immunol* 2001;**166**:4391–4398.
73. Tachimoto H, et al. Reciprocal regulation of cultured human mast cell cytokine production by IL-4 and IFN- γ . *J Allergy Clin Immunol* 2000;**106**:141–149.
74. Klemm S, et al. The Bcl10-Malt1 complex segregates Fc epsilon RI-mediated nuclear factor kappa B activation and cytokine production from mast cell degranulation. *J Exp Med* 2006;**203**:337–347.
75. Nishida K, et al. Fc{epsilon}RI-mediated mast cell degranulation requires calcium-independent microtubule-dependent translocation of granules to the plasma membrane. *J Cell Biol* 2005;**170**:115–126.
76. Hepp R, Puri N, Hohenstein AC, Crawford GL, Whiteheart SW, Roche PA. Phosphorylation of SNAP-23 regulates exocytosis from mast cells. *J Biol Chem* 2005;**280**:6610–6620.
77. Dimitriadou V, Lambracht-Hall M, Reichler J, Theoharides TC. Histochemical and ultrastructural characteristics of rat brain perivascular mast cells stimulated with compound 48/80 and carbachol. *Neuroscience* 1990;**39**:209–224.
78. Dimitriadou V, Buzzi MG, Moskowitz MA, Theoharides TC. Trigeminal sensory fiber stimulation induces morphologic changes reflecting secretion in rat dura mast cells. *Neuroscience* 1991;**44**:97–112.
79. Theoharides TC, Sant GR, El-Mansoury M, Letourneau RJ, Ucci AA Jr, Meares EM Jr. Activation of bladder mast cells in interstitial cystitis: a light and electron microscopic study. *J Urol* 1995;**153**:629–636.
80. Letourneau R, Pang X, Sant GR, Theoharides TC. Intragranular activation of bladder mast cells and their association with nerve processes in interstitial cystitis. *Br J Urol* 1996;**77**:41–54.
81. Dvorak AM, et al. Ultrastructural evidence for piecemeal and anaphylactic degranulation of human gut mucosal mast cells *in vivo*. *Int Arch Allergy Immunol* 1992;**99**:74–83.
82. Dvorak AM. Mast cell secretory granules and lipid bodies contain the necessary machinery important for the *in situ* synthesis of proteins. *Chem Immunol Allergy* 2005;**85**:252–315.
83. Tamir H, Theoharides TC, Gershon MD, Askenase PW. Serotonin storage pools in basophil leukemia and mast cells: characterization of two types of serotonin binding protein and radioautographic analysis of the intracellular distribution of [³H] serotonin. *J Cell Biol* 1982;**93**:638–647.
84. Spencer LA, Melo RC, Perez SA, Bafford SP, Dvorak AM, Weller PF. Cytokine receptor-mediated trafficking of preformed IL-4 in eosinophils identifies an innate immune mechanism of cytokine secretion. *Proc Natl Acad Sci USA* 2006;**103**:3333–3338.
85. Lessmann E, Leitges M, Huber M. A redundant role for PKC-epsilon in mast cell signaling and effector function. *Int Immunol* 2006;**18**:767–773.
86. Rivera J, Gilfillan AM. Molecular regulation of mast cell activation. *J Allergy Clin Immunol* 2006;**117**:1214–1225.
87. Furumoto Y, et al. Cutting edge: lentiviral short hairpin RNA silencing of PTEN in human mast cells reveals constitutive signals that promote cytokine secretion and cell survival. *J Immunol* 2006;**176**:5167–5171.
88. Stempelj M, Ferjan I. Signaling pathway in nerve growth factor induced histamine release from rat mast cells. *Inflamm Res* 2005;**54**:344–349.
89. Kandere-Grzybowska K, Kempuraj D, Cao J, Cetrulo CL, Theoharides TC. Regulation of IL-1-induced selective IL-6 release from human mast cells and inhibition by quercetin. *Br J Pharmacol* 2006;**148**:208–215.
90. Rivera J. Adaptors discriminate mast-cell cytokine production from eicosanoid production and degranulation. *Trends Immunol* 2006;**27**:251–253.
91. Jayapal M, et al. Genome-wide gene expression profiling of human mast cells stimulated by IgE or FcepsilonRI-aggregation reveals a complex network of genes involved in inflammatory responses. *BMC Genomics* 2006;**7**:210.
92. Rodriguez M. Multiple sclerosis: insights into molecular pathogenesis and therapy. *Mayo Clin Proc* 1997;**72**:663–664.
93. Smith KJ, McDonald WI. The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. *Philos Trans R Soc Lond B Biol Sci* 1999;**1390**:1649–1673.
94. Raine CS. Multiple sclerosis: immune system molecule expression in the central nervous system. *J Neuropathol Exp Neurol* 1994;**53**:328–337.
95. McFarland HF. Complexities in the treatment of autoimmune disease. *Science* 1996;**274**:2037–2038.
96. Lassmann H, Ransohoff RM. The CD4+Th1 model for multiple sclerosis: a crucial re-appraisal. *Trends Immunol* 2004;**25**:132–137.
97. Robbie-Ryan M, Tanzola MB, Secor VH, Brown MA. Cutting edge: both activating and inhibitory Fc receptors expressed on mast cells regulate experimental allergic encephalomyelitis disease severity. *J Immunol* 2003;**170**:1630–1634.
98. Pedotti R, De Voss JJ, Steinman L, Galli SJ. Involvement of both 'allergic' and 'autoimmune' mechanisms in EAE, MS and other autoimmune diseases. *Trends Immunol* 2003;**24**:479–484.
99. Pedotti R, et al. Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination. *Proc Natl Acad Sci USA* 2003;**100**:1867–1872.
100. Theoharides TC, Dimitriadou V, Letourneau RJ, Rozniecki JJ, Vliagoftis H, Boucher WS. Synergistic action of estradiol and myelin basic protein on mast cell secretion and brain demyelination: changes resembling early stages of demyelination. *Neuroscience* 1993;**57**:861–871.
101. Griffin DE, Mendoza QP. Identification of the inflammatory cells present in the central nervous system of normal and mast cell-deficient mice during Sindbis virus encephalitis. *Cell Immunol* 1986;**97**:454–459.
102. Mokhtarian F, Griffin DE. The role of mast cells in virus-induced inflammation in the murine central nervous system. *Cell Immunol* 1984;**86**:491–500.
103. Secor VH, Secor WE, Guteskunst C-A, Brown MA. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. *J Exp Med* 2000;**191**:813–821.
104. Robbie-Ryan M, Brown M. The role of mast cells in allergy and autoimmunity. *Curr Opin Immunol* 2002;**14**:728–733.
105. Brown MA, Tanzola M, Robbie-Ryan M. Mechanisms underlying mast cell influence on EAE disease course. *Mol Immunol* 2002;**38**:1373–1378.
106. Baram D, Vaday GG, Salamon P, Drucker I, Hershkovitz R, Mekori YA. Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF-alpha. *J Immunol* 2001;**167**:4008–4016.
107. Nakae S, Suto H, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. Mast cells enhance T cell activation: importance of mast cell-derived TNF. *Proc Natl Acad Sci USA* 2005;**102**:6467–6472.
108. Kempuraj D, et al. Myelin basic protein stimulates human mast cells and together they activate T cells: inhibition by luteolin and implications for multiple sclerosis. *Proc Keystone Symposia. Mast cells, basophils and Igb: Host defenses and diseases (Jan 20-24, 2007)*. Copper Mountain, CO:52.

109. Mohr DC, et al. Psychological stress and the subsequent appearances of new brain MRI lesions in MS. *Neurology* 2000;**55**:55–61.
110. Olsson Y. Mast cells in plaques of multiple sclerosis. *Acta Neurol Scand* 1974;**50**: 611–618.
111. Krüger PG, et al. Mast cells and multiple sclerosis: a light and electron microscopic study of mast cells in multiple sclerosis emphasizing staining procedures. *Acta Neurol Scand* 1990;**81**:31–36.
112. Kermodé AG, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. *Brain* 1990;**113**:1477–1489.
113. Lock C, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. *Nat Med* 2002;**8**:500–508.
114. Bompreszi R, et al. Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. *Hum Mol Genet* 2003;**12**: 2191–2199.
115. De Jager PL, Hafler DA. Gene expression profiling in MS: what is the clinical relevance? *Lancet Neurol* 2004;**3**:269.
116. Rozniecki JJ, Hauser SL, Stein M, Lincoln R, Theoharides TC. Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients. *Ann Neurol* 1995;**37**:63–66.
117. Malamud V, et al. Tryptase activates peripheral blood mononuclear cells causing the synthesis and release of TNF- α , IL-6 and IL-1 β : possible relevance to multiple sclerosis. *J Neuroimmunol* 2003;**138**: 115–122.
118. Bunnett NW. Protease-activated receptors: how proteases signal to cells to cause inflammation and pain. *Semin Thromb Hemost* 2006;**32**(Suppl.):39–48.
119. Steinhoff M, et al. Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. *Endocr Rev* 2005;**26**:1–43.
120. Ossovskaya VS, Bunnett NW. Protease-activated receptors: contribution to physiology and disease. *Physiol Rev* 2004;**84**:579–621.
121. Greenfeder S, et al. Tryptase-induced airway microvascular leakage in guinea pigs: involvement of tachykinins and leukotrienes. *Eur J Pharmacol* 2004;**419**:261–267.
122. De Vreis HE, Kuiper J, de Boer AG, Van Berkel TJC, Breimer DD. The blood-brain barrier in neuroinflammatory diseases. *Pharmacol Rev* 1997;**49**:143–155.
123. Moor ACE, de Vries HE, de Boer AG, Breimer DD. The blood-brain barrier and multiple sclerosis. *Biochem Pharmacol* 1994;**47**:1717–1724.
124. Kwon EE, Prineas JW. Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study. *J Neuropathol Exp Neurol* 1994;**53**:625–636.
125. Syndulko K, Tourtellotte WW, Conrad AJ, Izuierdo G, Multiple Sclerosis Study Group, Alpha Interferon Study Group. Trans-blood-brain-barrier albumin leakage and comparisons of intrathecal IgG synthesis calculations in multiple sclerosis patients. *J Neuroimmunol* 1993;**46**:185–192.
126. Theoharides TC. Mast cells: the immune gate to the brain. *Life Sci* 1990;**46**:607–617.
127. Letourneau R, Rozniecki JJ, Dimitriadou V, Theoharides TC. Ultrastructural evidence of brain mast cell activation without degranulation in monkey experimental allergic encephalomyelitis. *J Neuroimmunol* 2003;**145**:18–26.
128. Lambracht-Hall M, Dimitriadou V, Theoharides TC. Migration of mast cells in the developing rat brain. *Dev Brain Res* 1990;**56**:151–159.
129. Silverman AJ, Sutherland AK, Wilhelm M, Silver R. Mast cells migrate from blood to brain. *J Neurosci* 2000;**20**:401–408.
130. Wilhelm M, Silver R, Silverman AJ. Central nervous system neurons acquire mast cell products via transgranulation. *Eur J Neurosci* 2005;**22**:2238–2248.
131. Theoharides TC, Konstantinidou A. Corticotropin-releasing hormone and the blood-brain-barrier. *Front Biosci* 2007;**12**: 1615–1628.
132. Theoharides TC, et al. Stress-induced intracranial mast cell degranulation. A corticotropin releasing hormone-mediated effect. *Endocrinology* 1995;**136**:5745–5750.
133. Rozniecki JJ, Dimitriadou V, Lambracht-Hall M, Pang X, Theoharides TC. Morphological and functional demonstration of rat dura mast cell-neuron interactions *in vitro* and *in vivo*. *Brain Res* 1999;**849**:1–15.
134. Esposito P, et al. Corticotropin-releasing hormone (CRH) and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. *J Pharmacol Exp Ther* 2002;**303**:1061–1066.
135. Esposito P, et al. Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells. *Brain Res* 2001;**888**:117–127.
136. Chandler N, Jacobson S, Connolly R, Esposito P, Theoharides TC. Acute stress shortens the time of onset of experimental allergic encephalomyelitis (EAE) in SJL/J mice. *Brain Behav Immun* 2002;**16**:757–763.
137. Benou C, et al. Corticotropin-releasing hormone contributes to the peripheral inflammatory response in experimental autoimmune encephalomyelitis. *J Immunol* 2005;**174**:5407–5413.
138. Campbell T, et al. The effects of restraint stress on the neuropathogenesis of Theiler's virus infection: I. Acute disease. *Brain Behav Immun* 2001;**15**:235–254.
139. Sieve AN, et al. Chronic restraint stress during early Theiler's virus infection exacerbates the subsequent demyelinating disease in SJL mice. *J Neuroimmunol* 2004;**155**:103–118.
140. Singh LK, Pang X, Alexacos N, Letourneau R, Theoharides TC. Acute immobilization stress triggers skin mast cell degranulation via corticotropin releasing hormone, neurotensin and substance P: a link to neurogenic skin disorders. *Brain Behav Immun* 1999;**13**:225–239.
141. Theoharides TC, et al. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its pro-inflammatory effects. *Endocrinology* 1998;**139**:403–413.
142. Singh LK, et al. Potent mast cell degranulation and vascular permeability triggered by urocortin through activation of CRH receptors. *J Pharmacol Exp Ther* 1999;**288**:1349–1356.
143. Clifton VL, Crompton R, Smith R, Wright IM. Microvascular effects of CRH in human skin vary in relation to gender. *J Clin Endocrinol Metab* 2002;**87**:267–270.
144. Cao J, et al. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. *J Immunol* 2005;**174**:7665–7675.
145. Brown RF, Tennant CC, Dunn SM, Pollard JD. A review of stress-relapse interactions in multiple sclerosis: important features and stress-mediating and -moderating variables. *Mult Scler* 2005;**11**:477–484.
146. Goodin DS, Ebers GC, Johnson KP, Rodriguez M, Sibley WA, Wolinsky JS. The relationship of MS to physical trauma and psychological stress. *Neurology* 1999;**52**:1737–1745.
147. Warren S, Greenhill S, Warren KG. Emotional stress and the development of multiple sclerosis: case control evidence of a relationship. *J Chronic Dis* 1982;**35**:821–831.
148. Mei-Tal V, Meyerowitz S, Engel GL. The role of psychological process in a somatic disorder: multiple sclerosis. 1. The emotional setting of illness onset and exacerbation. *Psychosom Med* 1970;**32**:67–86.
149. Ackerman KD, et al. Robert Ader New Investigator award. Relationship of cardiovascular reactivity, stressful life events, and multiple sclerosis disease activity. *Brain Behav Immun* 2003;**17**:141–151.
150. Buljevac D, et al. Self reported stressful life events and exacerbations in multiple sclerosis: prospective study. *BMJ* 2003;**327**:646.

151. Li J, Johansen C, Bronnum-Hansen H, Stenager E, Koch-Henriksen N, Olsen J. The risk of multiple sclerosis in bereaved parents: a nationwide cohort study in Denmark. *Neurology* 2004;**62**:726–729.
152. Mohr DC, Hart SL, Julian L, Cox D, Pelletier D. Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. *BMJ* 2004;**328**:731.
153. Gold SM, Mohr DC, Huitinga I, Flachenecker P, Sternberg EM, Heesen C. The role of stress-response systems for the pathogenesis and progression of MS. *Trends Immunol* 2005;**26**:644–652.
154. Heesen C, Schulz H, Schmidt M, Gold S, Tessmer W, Schulz KH. Endocrine and cytokine responses to acute psychological stress in multiple sclerosis. *Brain Behav Immun* 2002;**16**:282–287.
155. Huang M, Pang X, Karalis K, Theoharides TC. Stress-induced interleukin-6 release in mice is mast cell-dependent and more pronounced in Apolipoprotein E knockout mice. *Cardiovasc Res* 2003;**59**:241–249.
156. Lalive PH, Burkhard PR, Chofflon M. TNF-alpha and psychologically stressful events in healthy subjects: potential relevance for multiple sclerosis relapse. *Behav Neurosci* 2002;**116**:1093–1097.
157. Fox RJ, Ransohoff RM. New directions in MS therapeutics: vehicles of hope. *Trends Immunol* 2004;**25**:632–636.
158. Zappulla JP, Arock M, Mars LT, Liblau RS. Mast cells: new targets for multiple sclerosis therapy? *J Neuroimmunol* 2002;**131**:5–20.
159. Shin HY, Kim JS, An NH, Park RK, Kim HM. Effect of disodium cromoglycate on mast cell-mediated immediate-type allergic reactions. *Life Sci* 2004;**74**:2877–2887.
160. Theoharides TC, Sieghart W, Greengard P, Douglas WW. Antiallergic drug cromolyn may inhibit histamine secretion by regulating phosphorylation of a mast cell protein. *Science* 1980;**207**:80–82.
161. Theoharides TC, et al. Chondroitin sulfate inhibits connective tissue mast cells. *Br J Pharmacol* 2000;**131**:1039–1049.
162. Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. *Pharmacol Rev* 2000;**52**:673–751.
163. Kempuraj D, et al. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. *Br J Pharmacol* 2005;**145**:934–944.
164. Shichijo M, Yamamoto N, Tsujishita H, Kimata M, Nagai H, Kokubo T. Inhibition of syk activity and degranulation of human mast cells by flavonoids. *Biol Pharm Bull* 2003;**26**:1685–1690.
165. Sieghart W, Theoharides TC, Douglas WW, Greengard P. Phosphorylation of a single mast cell protein in response to drugs that inhibit secretion. *Biochem Pharmacol* 1981;**30**:2737–2738.
166. Correia I, Wang L, Pang X, Theoharides TC. Characterization of the 78 kDa mast cell protein phosphorylated by the antiallergic drug cromolyn and homology to moesin. *Biochem Pharmacol* 1996;**52**:413–424.
167. Bachelet I, Munitz A, Moretta A, Moretta L, Levi-Schaffer F. The inhibitory receptor IRp60 (CD300a) is expressed and functional on human mast cells. *J Immunol* 2005;**175**:7989–7995.
168. Cherwinski HM, et al. The CD200 receptor is a novel and potent regulator of murine and human mast cell function. *J Immunol* 2005;**174**:1348–1356.
169. Andrasfalvy M, et al. The beta subunit of the type I Fcepsilon receptor is a target for peptides inhibiting IgE-mediated secretory response of mast cells. *J Immunol* 2005;**175**:2801–2806.
170. Forssell J, et al. Interleukin-2-inducible T cell kinase regulates mast cell degranulation and acute allergic responses. *Am J Respir Cell Mol Biol* 2005;**32**:511–520.
171. Davis BJ, Flanagan BF, Gilfillan AM, Metcalfe DD, Coleman JW. Nitric oxide inhibits IgE-dependent cytokine production and Fos and Jun activation in mast cells. *J Immunol* 2004;**173**:6914–6920.
172. Hendriks JJ, de Vries HE, van der Pol SM, van den Berg TK, van Tol EA, Dijkstra CD. Flavonoids inhibit myelin phagocytosis by macrophages; a structure-activity relationship study. *Biochem Pharmacol* 2003;**65**:877–885.
173. Aktas O, et al. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. *J Immunol* 2004;**173**:5794–5800.
174. Hendriks JJ, Alblas J, van der Pol SM, van Tol EA, Dijkstra CD, de Vries HE. Flavonoids influence monocytic GTPase activity and are protective in experimental allergic encephalitis. *J Exp Med* 2004;**200**:1667–1672.
175. Verbeek R, Plomp AC, van Tol EA, van Noort JM. The flavones luteolin and apigenin inhibit in vitro antigen-specific proliferation and interferon-gamma production by murine and human autoimmune T cells. *Biochem Pharmacol* 2004;**68**:621–629.
176. Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D, Conti P. Mast cells as targets of corticotropin-releasing factor and related peptides. *Trends Pharmacol Sci* 2004;**25**:563–568.
177. Theoharides TC, Kalogeromitros D. The critical role of mast cell in allergy and inflammation. *Ann NY Acad Sci* 2006;**1088**:78–99.
178. Paus R, Theoharides TC, Arck PC. Neuro-immunoendocrine circuitry of the 'brain-skin connection'. *Trends Immunol* 2006;**27**:32–39.
179. Theoharides TC, Papaliodis D, Tagen M, Konstantinidou A, Kempuraj D, Clemons A. Chronic fatigue syndrome, mast cells, and tricyclic antidepressants. *J Clin Psychopharmacol* 2005;**25**:515–520.
180. Lucas HJ, Brauch CM, Settas L, Theoharides TC. Fibromyalgia – new concepts of pathogenesis and treatment. *Int J Immunopathol Pharmacol* 2006;**19**:5–10.
181. Theoharides TC. Synovial mast cells in inflammatory arthritis. In: Meyers ED, ed. *Encyclopedia of Molecular Cell Biology and Molecular Medicine*. Larkspur, CA: Ramtech Ltd., 2005:37–63.
182. Theoharides TC, Kempuraj D, Sant GR. Mast cell involvement in interstitial cystitis: a review of human and experimental evidence. *Urology* 2001;**57**:47–55.
183. Theoharides T, Sant GR. Immunomodulators for the treatment of interstitial cystitis. *Urology* 2005;**65**:633–638.
184. Theoharides TC, Donelan J, Kandere-Grzybowska K, Konstantinidou A. The role of mast cells in migraine pathophysiology. *Brain Res Rev* 2005;**49**:65–76.
185. Lin TJ, Hirji N, Nohara O, Stenton GR, Gilchrist M, Befus AD. Mast cells express novel CD8 molecules that selectively modulate mediator secretion. *J Immunol* 1998;**161**:6265–6272.
186. Papadopoulou NG, Oleson L, Kempuraj D, Donelan J, Cetrulo CL, Theoharides TC. Regulation of corticotropin-releasing hormone receptor-2 expression in human cord blood-derived cultured mast cells. *J Mol Endocrinol* 2005;**35**:R1–R8.
187. Coulombe M, Battistini B, Stankova J, Pouliot P, Bissonnette EY. Endothelins regulate mediator production of rat tissue-cultured mucosal mast cells. Up-regulation of Th1 and inhibition of Th2 cytokines. *J Leukoc Biol* 2002;**71**:829–836.
188. Hogaboam CM, Befus AD, Wallace JL. Modulation of rat mast cell reactivity by IL-1 beta. Divergent effects on nitric oxide and platelet-activating factor release. *J Immunol* 1993;**151**:3767–3774.

189. Gupta AA, Leal-Berumen I, Croitoru K, Marshall JS. Rat peritoneal mast cells produce IFN- γ following IL-12 treatment but not in response to IgE-mediated activation. *J Immunol* 1996;**157**:2123–2128.
190. Mellor EA, Austen KF, Boyce JA. Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists. *J Exp Med* 2002;**195**:583–592.
191. Kalesnikoff J, et al. Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival. *Immunity* 2001;**14**:801–811.
192. Leal-Berumen I, O'Byrne P, Gupta A, Richards CD, Marshall JS. Prostanoid enhancement of interleukin-6 production by rat peritoneal mast cells. *J Immunol* 1995;**154**:4759–4767.
193. Gordon JR, Zhang X, Stevenson K, Cosford K. Thrombin induces IL-6 but not TNF- α secretion by mouse mast cells: threshold-level thrombin receptor and very low level Fc ϵ RI signaling synergistically enhance IL-6 secretion. *Cell Immunol* 2000;**205**:128–135.
194. Leal-Berumen I, Snider DP, Barajas-Lopez C, Marshall JS. Cholera toxin increases IL-6 synthesis and decreases TNF- α production by rat peritoneal mast cells. *J Immunol* 1996;**156**:316–321.